secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001125345-23-000109
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q2 net income $57.5M on royalty gain; $50M TZIELD milestone from Sanofi
--------------------------------------------------------------------------------

- Net income of $57.5M ($0.92 diluted EPS) vs net loss of $41.3M a year ago; driven by $100.9M gain on royalty monetization.
- Total revenue $13.1M, down from $26.0M YoY; collaborative revenue fell to $6.0M from $16.9M.
- Cash $240.3M; plus $50M Sanofi milestone; cash runway extends into 2026.
- Pipeline: TAMARACK Phase 2 for vobra duo in mCRPC enrolling under amended protocol; lorigerlimab Phase 2 to start.
- Received $50M milestone from Sanofi after positive TZIELD Phase 3 data; additional $50M possible if net sales threshold met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/0001125345-23-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000109/mgnx-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer